273 related articles for article (PubMed ID: 23590927)
21. [Minor neurological and physical anomalies in patients with first-episode psychosis].
Mhalla A; Boussaïd N; Gassab L; Gaha L; Mechri A
Encephale; 2013 Jun; 39(3):149-54. PubMed ID: 23095597
[TBL] [Abstract][Full Text] [Related]
22. Impact of tobacco, alcohol and cannabis use on treatment outcomes among patients experiencing first episode psychosis: Data from the national RAISE-ETP study.
Oluwoye O; Monroe-DeVita M; Burduli E; Chwastiak L; McPherson S; McClellan JM; McDonell MG
Early Interv Psychiatry; 2019 Feb; 13(1):142-146. PubMed ID: 29356438
[TBL] [Abstract][Full Text] [Related]
23. The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study.
Degenhardt L; Tennant C; Gilmour S; Schofield D; Nash L; Hall W; McKay D
Psychol Med; 2007 Jul; 37(7):927-34. PubMed ID: 17288638
[TBL] [Abstract][Full Text] [Related]
24. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study.
Caseiro O; Pérez-Iglesias R; Mata I; Martínez-Garcia O; Pelayo-Terán JM; Tabares-Seisdedos R; Ortiz-García de la Foz V; Vázquez-Barquero JL; Crespo-Facorro B
J Psychiatr Res; 2012 Aug; 46(8):1099-105. PubMed ID: 22721546
[TBL] [Abstract][Full Text] [Related]
25. Stability and development of psychotic symptoms and the use of antipsychotic medication - long-term follow-up.
Gotfredsen DR; Wils RS; Hjorthøj C; Austin SF; Albert N; Secher RG; Thorup AAE; Mors O; Nordentoft M
Psychol Med; 2017 Sep; 47(12):2118-2129. PubMed ID: 28382874
[TBL] [Abstract][Full Text] [Related]
26. Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial.
Bertelsen M; Jeppesen P; Petersen L; Thorup A; Øhlenschlaeger J; le Quach P; Christensen TØ; Krarup G; Jørgensen P; Nordentoft M
Arch Gen Psychiatry; 2008 Jul; 65(7):762-71. PubMed ID: 18606949
[TBL] [Abstract][Full Text] [Related]
27. Effect of cannabis on weight and metabolism in first-episode non-affective psychosis: Results from a three-year longitudinal study.
Vázquez-Bourgon J; Setién-Suero E; Pilar-Cuéllar F; Romero-Jiménez R; Ortiz-García de la Foz V; Castro E; Crespo-Facorro B
J Psychopharmacol; 2019 Mar; 33(3):284-294. PubMed ID: 30702972
[TBL] [Abstract][Full Text] [Related]
28. [Catatonia in a 14 year-old girl: treatment with clorazepam and carbamazepine, a 10-year follow-up].
Askenazy F; Dor E; Benoit M; Dupuis G; Serret S; Myquel M; Seddiki Y
Encephale; 2010 Feb; 36(1):46-53. PubMed ID: 20159196
[TBL] [Abstract][Full Text] [Related]
29. Antipsychotic medication and remission of psychotic symptoms 10years after a first-episode psychosis.
Wils RS; Gotfredsen DR; Hjorthøj C; Austin SF; Albert N; Secher RG; Thorup AA; Mors O; Nordentoft M
Schizophr Res; 2017 Apr; 182():42-48. PubMed ID: 28277310
[TBL] [Abstract][Full Text] [Related]
30. Reasons for cannabis use and effects of cannabis use as reported by patients with psychotic disorders.
Dekker N; Linszen DH; De Haan L
Psychopathology; 2009; 42(6):350-60. PubMed ID: 19752588
[TBL] [Abstract][Full Text] [Related]
31. A Study of the Impact of Cannabis on Doses of Discharge Antipsychotic Medication in Individuals with Schizophrenia or Schizoaffective Disorder.
Babatope T; Chotalia J; Elkhatib R; Mohite S; Shah J; Goddu S; Patel RA; Aimienwanu OR; Patel D; Makanjuola T; Okusaga OO
Psychiatr Q; 2016 Dec; 87(4):729-737. PubMed ID: 26875104
[TBL] [Abstract][Full Text] [Related]
32. Dose-response effect between cannabis use and psychosis liability in a non-clinical population: evidence from a snowball sample.
Ruiz-Veguilla M; Barrigón ML; Hernández L; Rubio JL; Gurpegui M; Sarramea F; Cervilla J; Gutiérrez B; James A; Ferrin M
J Psychiatr Res; 2013 Aug; 47(8):1036-43. PubMed ID: 23684550
[TBL] [Abstract][Full Text] [Related]
33. Impacts of duration of untreated psychosis on cognition and negative symptoms in first-episode schizophrenia: a 3-year prospective follow-up study.
Chang WC; Hui CL; Tang JY; Wong GH; Chan SK; Lee EH; Chen EY
Psychol Med; 2013 Sep; 43(9):1883-93. PubMed ID: 23217676
[TBL] [Abstract][Full Text] [Related]
34. Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls.
Korver N; Nieman DH; Becker HE; van de Fliert JR; Dingemans PH; de Haan L; Spiering M; Schmitz N; Linszen DH
Aust N Z J Psychiatry; 2010 Mar; 44(3):230-6. PubMed ID: 20180725
[TBL] [Abstract][Full Text] [Related]
35. The EPPIC follow-up study of first-episode psychosis: longer-term clinical and functional outcome 7 years after index admission.
Henry LP; Amminger GP; Harris MG; Yuen HP; Harrigan SM; Prosser AL; Schwartz OS; Farrelly SE; Herrman H; Jackson HJ; McGorry PD
J Clin Psychiatry; 2010 Jun; 71(6):716-28. PubMed ID: 20573330
[TBL] [Abstract][Full Text] [Related]
36. Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis: the CapOpus randomized trial.
Hjorthøj CR; Fohlmann A; Larsen AM; Gluud C; Arendt M; Nordentoft M
Psychol Med; 2013 Jul; 43(7):1499-510. PubMed ID: 23040144
[TBL] [Abstract][Full Text] [Related]
37. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people.
Henquet C; Krabbendam L; Spauwen J; Kaplan C; Lieb R; Wittchen HU; van Os J
BMJ; 2005 Jan; 330(7481):11. PubMed ID: 15574485
[TBL] [Abstract][Full Text] [Related]
38. Age at onset of non-affective psychosis in relation to cannabis use, other drug use and gender.
Dekker N; Meijer J; Koeter M; van den Brink W; van Beveren N; Kahn RS; Linszen DH; van Os J; Wiersma D; Bruggeman R; Cahn W; de Haan L; Krabbendam L; Myin-Germeys I;
Psychol Med; 2012 Sep; 42(9):1903-11. PubMed ID: 22452790
[TBL] [Abstract][Full Text] [Related]
39. Cannabis as a risk factor for psychosis: systematic review.
Semple DM; McIntosh AM; Lawrie SM
J Psychopharmacol; 2005 Mar; 19(2):187-94. PubMed ID: 15871146
[TBL] [Abstract][Full Text] [Related]
40. Premorbid cannabis use is associated with more symptoms and poorer functioning in schizophrenia spectrum disorder.
Ringen PA; Nesvåg R; Helle S; Lagerberg TV; Lange EH; Løberg EM; Agartz I; Andreassen OA; Melle I
Psychol Med; 2016 Nov; 46(15):3127-3136. PubMed ID: 27534999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
